Latest Anaplastic lymphoma kinase Stories
- Ceritinib achieved overall response rate of 58.5%, with a median progression-free survival of 8.2 months1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today announced data showing
Advances in Neuroblastoma Research Association Recognizes Physician-Investigator's Progress Against a Challenging Childhood Cancer Philadelphia, Pa (PRWEB)
Ceritinib (brand name Zykadia(TM)) will be used for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or
- Zykadia (ceritinib) demonstrated an overall response rate of 54.6% in patients with ALK+ metastatic NSCLC who have no other treatment option EAST HANOVER, N.J., April 29, 2014 /PRNewswire/
- Data showed investigational treatment LDK378 (ceritinib) also achieved a median progression-free survival of seven months EAST HANOVER, N.J., March 26, 2014 /PRNewswire/ -- Novartis today
The findings of a recent study indicate that routine testing with both fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) may enhance the detection of ALK-positive non-small cell lung cancer (NSCLC).
A University of Colorado Cancer Center study published today in the International Journal of Radiation Oncology Biology and Physics shows that patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease.
A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers.
PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.